Table 5.
Summary of clinical care outcomes in 353 individuals with a diagnosis of chronic HCV infection
| Treatment Status | Patient Classification | Number | Percentage of treatment subgroupa | Percentage of total cohort |
| Not yet treated (n = 130) |
Offered appointment but did not attend | 46 | 35.4 | 13.0 |
| Seen in another clinic (sexual health, prison, paediatrics) | 32 | 24.6 | 9.1 | |
| Seen by hepatology but not on treatment waiting list | 23 | 17.7 | 6.5 | |
| Seen by hepatology and on treatment waiting list for DAA | 3 | 2.3 | 0.9 | |
| Died | 11 | 8.5 | 3.1 | |
| Transferred out of area | 10 | 7.7 | 2.8 | |
| Seen in clinic but lost to follow-up | 2 | 1.5 | 0.6 | |
| Spontaneous clearer | 3 | 2.3 | 0.8 | |
| Treated with DAA (n = 59) |
SVR12 | 50 | 84.7 | 14.2 |
| Relapsed | 4 | 6.8 | 1.1 | |
| Outcome data pending | 5 | 8.5 | 1.4 | |
| Treated with IFN/RBV (n = 20) |
SVR12 | 16 | 80.0 | 4.5 |
| Relapsed | 3 | 15.0 | 0.8 | |
| No outcome data | 1 | 5.0 | 0.3 | |
| Unknown (n = 150) |
Not known to local services | 144 | 100 | 40.8 |
| TOTAL | 353 | 400 | 100 |
aTreatment subgroup is defined as the four categories listed in the first column of this table. The total of this column is 300%, as the total for each of three subgroups is 100%
DAA = direct acting antivirals, IFN = interferon, RBV = ribavirin; SVR12 = sustained viraemic response at ≥12 weeks following therapy